BRAVE Study Investigates Adenosine Pathway in Drug-Resistant Epilepsy and SUDEP Risk
The BRAVE study, sponsored by Hospices Civils de Lyon, is currently investigating alterations in adenosine receptors (ARs) within the brainstem of patients with drug-resistant epilepsy. This trial specifically examines the relationship between these receptor alterations and respiratory dysfunction,
Phase III
Neurology / Epilepsy
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
Findings from the BRAVE study could inform the development of new therapeutic strategies targeting adenosine receptors to address respiratory dysfunction and reduce SUDEP risk, influencing portfolio prioritization and potential licensing opportunities for novel interventions.
Why it matters
The BRAVE study's exploration of adenosine receptors in drug-resistant epilepsy patients addresses a critical gap in understanding the relationship between respiratory dysfunction and arousal, which is essential for developing effective treatments.
Recommended action
Humanexa recommends Monitor: Monitoring the BRAVE study is essential as it may yield insights that could reshape treatment approaches for drug-resistant epilepsy and SUDEP risk. The study's focus on adenosine receptors could lead to significant clinical implications, making it crucial to stay informed about its progress and outcomes to assess potential impacts on future drug development and market opportunities.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.